- Home
- BJDX vs ONCO Comparison
BJDX vs ONCO Comparison
Compare BJDX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- ONCO
- Stock Information
- Founded
- BJDX 2015
- ONCO 2018
- Country
- BJDX United States
- ONCO United States
- Employees
- BJDX N/A
- ONCO N/A
- Industry
- BJDX Medical Specialities
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- ONCO Health Care
- Exchange
- BJDX Nasdaq
- ONCO Nasdaq
- Market Cap
- BJDX 2.2M
- ONCO 1.8M
- IPO Year
- BJDX 2021
- ONCO 2022
- Fundamental
- Price
- BJDX $3.70
- ONCO $0.08
- Analyst Decision
- BJDX
- ONCO
- Analyst Count
- BJDX 0
- ONCO 0
- Target Price
- BJDX N/A
- ONCO N/A
- AVG Volume (30 Days)
- BJDX 35.9K
- ONCO 9.4M
- Earning Date
- BJDX 05-14-2025
- ONCO 05-19-2025
- Dividend Yield
- BJDX N/A
- ONCO N/A
- EPS Growth
- BJDX N/A
- ONCO N/A
- EPS
- BJDX N/A
- ONCO N/A
- Revenue
- BJDX N/A
- ONCO $1,870,605.00
- Revenue This Year
- BJDX N/A
- ONCO N/A
- Revenue Next Year
- BJDX N/A
- ONCO N/A
- P/E Ratio
- BJDX N/A
- ONCO N/A
- Revenue Growth
- BJDX N/A
- ONCO N/A
- 52 Week Low
- BJDX $3.03
- ONCO $0.07
- 52 Week High
- BJDX $316.80
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- BJDX 45.28
- ONCO 19.12
- Support Level
- BJDX $3.52
- ONCO $0.07
- Resistance Level
- BJDX $4.02
- ONCO $0.15
- Average True Range (ATR)
- BJDX 0.32
- ONCO 0.02
- MACD
- BJDX -0.05
- ONCO 0.01
- Stochastic Oscillator
- BJDX 14.06
- ONCO 16.82
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.